peptide analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-21. Numbers and descriptions here follow the published literature rather than marketing material.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
== T == Koichi Tanaka (born 1959), Japanese electrical engineer, 2002 Nobel Prize in Chemistry Henry Taube (1915–2005), American chemist, (1983 Nobel Prize in Chemistry Louis Jacques Thénard (1777–1857), French chemist, discovered hydrogen peroxide and Thenard's Blue Sir Harold Warris Thompson (1908–1983), English physical chemist J. J. Thomson (1856–1940), British physicist, Known in chemistry for discovery of isotopes T. Don Tilley (born 1954), organometallic chemist Arne Tiselius (1902–1971), Swedish biochemist, 1948 Nobel Prize in Chemistry Max Tishler (1906–1989), American chemist, 1970 Priestley Medal Alexander R. Todd, Baron Todd (1907–1997), British biochemist, 1957 Nobel Prize in Chemistry Evangelista Torricelli (1608–1647), Italian physicist and chemist, invented the barometer, pupil of Galileo Roger Y. Tsien (1952–2016), American biochemist, 2008 Nobel Prize in Chemistry Mikhail Tsvet (1872–1919), Russian botanist, known for adsorption chromatography Kristy Turner, British chemist
"Ligament" most commonly refers to a band of dense regular connective tissue bundles made of collagenous fibers, with bundles protected by dense irregular connective tissue sheaths. Ligaments connect bones to other bones to form joints, while tendons connect bone to muscle. Some ligaments limit the mobility of articulations or prevent certain movements altogether. Capsular ligaments are part of the articular capsule that surrounds synovial joints. They act as mechanical reinforcements. Extra-capsular ligaments join in harmony with the other ligaments and provide joint stability. Intra-capsular ligaments, which are much less common, also provide stability but permit a far larger range of motion. Cruciate ligaments are paired ligaments in the form of a cross. Ligaments are viscoelastic. They gradually strain when under tension and return to their original shape when the tension is removed. However, they cannot retain their original shape when extended past a certain point or for a prolonged period of time. This is one reason why dislocated joints must be set as quickly as possible: if the ligaments lengthen too much, then the joint will be weakened, becoming prone to future dislocations. Athletes, gymnasts, dancers, and martial artists perform stretching exercises to lengthen their ligaments, making their joints more supple. The term hypermobility refers to the characteristic of people with more-elastic ligaments, allowing their joints to stretch and contort further; this is sometimes still called double-jointedness.
== Ecological importance == Anaerobic respiration is a critical component of the global nitrogen, iron, sulfur, and carbon cycles through the reduction of the oxyanions of nitrogen, sulfur, and carbon to more-reduced compounds. The biogeochemical cycling of these compounds, which depends upon anaerobic respiration, significantly impacts the carbon cycle and global warming. Anaerobic respiration occurs in many environments, including freshwater and marine sediments, soil, subsurface aquifers, deep subsurface environments, and biofilms. Even environments that contain oxygen, such as soil, have micro-environments that lack oxygen due to the slow diffusion characteristics of oxygen gas. An example of the ecological importance of anaerobic respiration is the use of nitrate as a terminal electron acceptor, or dissimilatory denitrification, which is the main route by which fixed nitrogen is returned to the atmosphere as molecular nitrogen gas. The denitrification process is also very important in host-microbe interactions. Like mitochondria in oxygen-respiring microorganisms, some single-cellular anaerobic ciliates use denitrifying endosymbionts to gain energy. Another example is methanogenesis, a form of carbon-dioxide respiration, that is used to produce methane gas by anaerobic digestion. Biogenic methane can be a sustainable alternative to fossil fuels. However, uncontrolled methanogenesis in landfill sites releases large amounts of methane into the atmosphere, acting as a potent greenhouse gas.
April 1973: The Movement for the Freedom of Abortion and Contraception (MLAC) is created; it includes feminist and political organizations and announces the practice of then-illegal abortions (Karman method) and group trips abroad for abortion. July 11, 1973: Creation of the Higher Council for Sexual Information, Birth Control, and Family Education. October 8, 1973: Ministerial order extending national agreements concluded in the metallurgy sector; part of it concerns maternity leave compensation. May 1974: Simone Veil becomes Minister of Health; five other women serve as Secretaries of State between 1974 and 1976. July 16, 1974: Creation of the back-to-school allowance. July 23, 1974: The State Secretariat for the Status of Women is created; attached to the Prime Minister, it is assigned to Françoise Giroud. December 4, 1974: Law with various provisions regarding birth control. January 17, 1975: Law of January 17, 1975 on voluntary termination of pregnancy (abortion), also called the "Veil Law," which decriminalizes abortion; adopted for a five-year trial period. Its implementing decree was published on May 13, 1975, providing further details. July 10, 1975: Law amending Article 7 of Ordinance 59-244 of February 4, 1959 (no distinction is made between men and women for the application of this ordinance, except in certain cases where exclusive recruitment of men or women may be planned). July 11, 1975: Law reforming divorce.
==== Early synthesis by the Buddha ==== According to Erich Frauwallner, the twelvefold chain resulted from the Buddha's combination of two lists. Originally, the Buddha explained the appearance of dukkha from tanha, "thirst", craving. Later on, the Buddha incorporated avijja, "ignorance", as a cause of suffering into his system. This is described in the first part of dependent origination. Frauwallner saw this "purely mechanical mixing" as "enigmatical", "contradictory" and a "deficiency in systematization". Paul Williams discusses Frauwallner's idea that the 12 links may be a composite. However, he ultimately concludes that "it may be impossible at our present stage of scholarship to work out very satisfactorily what the original logic of the full twelvefold formula was intended to be, if there ever was one intention at all."
Sources: en.wikipedia.org
These resynthesis experiments provided strong evidence: lichens are a product of symbiosis. The dual hypothesis gained influential supporters; in 1878, Royal Society president Joseph Hooker publicly endorsed Schwendener's theory in his annual address, and by 1880 leading British and American textbooks presented lichens as dual organisms. By 1900 the consensus had shifted. Most botanists now viewed lichens as fungi partnered with algae or cyanobacteria and reclassified them accordingly. Dissent lingered. In a 1909 poll of 42 botanists, Bruce Fink found 18 calling lichens dual organisms, 14 insisting they were fungi, and the rest undecided. Yet even holdouts were beginning to adopt the dual view. The Finnish lichenologist Edvard Vainio (1890) folded lichens into a fungal scheme—labelling them fungi that happen to form symbioses—a move said to have cost him a professorship. The next puzzle was how to classify lichens now that their dual nature was clear. Taxonomists questioned whether to base classification on fungal traits, algal traits, or both. In practice, they chose the fungus. Since the fungus governs reproduction and form, its fruiting bodies and spores carried the most taxonomic weight. By the late 1800s, taxonomists grouped lichens by fungal traits—spore colour, septation, fruiting-body type—rather than thallus shape or algal partner. The shift broke with thallus-based schemes and aligned lichen study with modern fungal taxonomy.
Afterwards, John left Earth for space, where he participated in the Cosmic Odyssey miniseries event, and failed to prevent the destruction of the planet Xanshi by an avatar of the Anti-Life Equation. The incident earned him the ire of Martian Manhunter, who was with him at the time. This series of tragedies left John a shattered man on the brink of suicide and created the villainess known as Fatality, the sole survivor of Xanshi. Martian Manhunter has since, at least civilly, forgiven him.
Weapon No. 2, which underwent something other than normal release from the aircraft, evidenced by the fact that the parachute did not deploy, also had its arming rods extracted, and those components which were given the opportunity to act, did act in the manner expected. Full operation of this weapon was prevented by several things: Impact occurred so soon after separation of the Bisch rods that the timers were not given an opportunity to run down. The Arm/Safe Switch was in the "Safe" condition as the weapon left the aircraft. Another analysis by Sandia engineers in 1961 concluded that while in both weapons the MC-772 Arm/Safe Switch operated "as it was designed to do," the lanyard-controlled safing-pins "cannot be relied upon to prevent initiation of the fuzing sequence" in this kind of accident, and recommended implementing a modification to the weapons "as rapidly as possible" that would prevent the fuze power supply from activating except when live release was intended. A 1969 analysis by Sandia supervisor Parker F. Jones concluded that the Goldsboro accident illustrated that "the Mk 39 Mod 2 bomb did not possess adequate safety for the airborne alert role in the B-52."
Butyrylcholinesterase deficiency (also known as pseudocholinesterase deficiency, and Succinylcholine Sensitivity is an autosomal recessive inherited blood plasma enzyme abnormality in which the body's production of butyrylcholinesterase (BChE) is impaired. People who have this abnormality may be sensitive to certain anesthetic drugs, including the muscle relaxants succinylcholine and mivacurium as well as other ester local anesthetics. It is classed as an inborn error of metabolism in ICD11.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.